Pretransplant angiotensin II type 1-receptor antibodies point to an increase in renal graft sub-intimal fibrosis in living- donor kidney transplant recipients

The association between anti-AT1Rabs and microvascular injury observed in antibody-mediated rejection has been described in kidney graft Biopsies (KGBx). We herein describe the histopathologic findings of KGBx performed during the first year of transplantation (Tx) in 134 patients tested for pre-Tx...

Full description

Saved in:
Bibliographic Details
Published in:Transplant immunology 2019-06, Vol.54, p.1-8
Main Authors: González-Almada, Alberto, Arreola-Guerra, José M., López-Sánchez, José Argenis, Cuevas, Eric, Vilatoba, Mario, Contreras, Alan G., Morales-Buenrostro, Luis E., Alberu, Josefina, Uribe-Uribe, Norma O.
Format: Article
Language:English
Subjects:
Acute allograft rejection
Adolescent
Adult
Allografts - blood supply
Allografts - pathology
Angiotensin II type 1 receptor antibodies
Antibodies - blood
Female
Fibrosis
Graft Occlusion, Vascular - epidemiology
Graft Rejection - diagnosis
Graft Rejection - epidemiology
Graft Rejection - immunology
Histology
Humans
Kidney - blood supply
Kidney - pathology
Kidney Transplantation
Living Donors
Male
Mexico - epidemiology
Receptor, Angiotensin, Type 1 - immunology
Renal transplantation
Sub-intimal fibrosis
Transplant Recipients
Tunica Intima - pathology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The association between anti-AT1Rabs and microvascular injury observed in antibody-mediated rejection has been described in kidney graft Biopsies (KGBx). We herein describe the histopathologic findings of KGBx performed during the first year of transplantation (Tx) in 134 patients tested for pre-Tx anti-AT1Rabs in cryopreserved sera (04/2009 to 09/2013). Protocol KGBx before implantation (time-zero), 1 year after Tx and for cause KGBx were included. 21/134 Tx patients were anti-AT1Rab positive (≥17 U/mL); 7/21 experienced acute rejection. For comparison a control group with anti-AT1Rabs
ISSN:0966-3274
1878-5492
DOI:10.1016/j.trim.2018.10.003